Trial Profile
An Open Label Study to Evaluate the Pharmacokinetics of YM150 After a Single Oral Dose of C14-labeled YM150 in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2014
Price :
$35
*
At a glance
- Drugs Darexaban (Primary)
- Indications Thromboembolism; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Europe Ltd
- 14 Aug 2012 New trial record